Fagron stock

FAGR · Euronext Brussels · EUR

Compare Fagron
€24.40Change from previous close: +0.41%Absolute change: +€0.10

Close · November 17, 2026

Price history

+19.61% over the period

1 year: from €20.40 (November 17, 2025) to €24.40 (November 17, 2026), +19.61%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 17, 2026€24.40
October 30, 2026€23.45
September 30, 2026€23.25
August 31, 2026€22.25
July 31, 2026€23.20
June 30, 2026€24.10
May 29, 2026€24.10
April 30, 2026€24.00
March 31, 2026€21.60
February 27, 2026€22.75
January 30, 2026€22.15
December 31, 2025€21.30
November 28, 2025€21.30
November 17, 2025€20.40

At a glance

  • The company

    Pharmaceutical compounding company delivering personalized care products and services to hospitals, pharmacies, clinics and patients worldwide

  • Latest results

    Quarter to September 30, 2026

TickerLandia's take on Fagron

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low€20.00
52-wk high€25.30

−3.56% from the 52-week high

Analysts · 6 analysts

Average target€29.00+18.85% vs. price

Buy 6 · Hold 0 · Sell 0 · Strong buy

TickerLandia Fingerprint: Fagron

Compared with similar companies: high earnings stability, low risk, and low price.

Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Fagron is priced as in the past and in line with similar companies

On the latest fiscal year's earnings (2025), Fagron's P/E today is 19.7, in line with the median of its last 9 fiscal years (17.6; between 13.9 and 25.8 from 2017 to 2025). Fagron's P/E (trailing 12 months): 18.8, in line with the median of a group of 10 similar companies (19.0).

P/E compared with its history

Compared with 10 similar companies

Fagron's metrics compared with similar companies
MetricFagronPosition in the groupBand
P/E (trailing 12 months)18.8Middle
Forward P/E15.9Middle
Operating margin14.3%Middle
ROE16.7%Middle
Debt/equity1.06High

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Fagron. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

€552.48M

Latest quarter · Q2 2026

Net income

€46.28M

Latest quarter · Q2 2026

Quarterly net margin

8.4%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
€1.73B
P/E
18.8
EPS
€1.25
Volume
138.87K
Daily trading
€2.42M
Dividend yield
1.64%
Last ex-dividend on May 18, 2026

How Fagron is changing

All results
  • Revenue grew 11.4% a year on average over the last 5 years

  • Operating margin rose from 13.4% to 15.2%

  • Profits turn into cash: free cash flow equal to 135% of net income

Returns

Fagron returns with dividends

€1,000 invested in Fagron 5 years ago, on November 17, 2021, would be worth €1,830 today with dividends reinvested: +83.00% in total, +12.85% per year. On price alone it would be €1,697 (+69.68%).

PeriodFagron€1,000 becomes
1 month+4.95%€1,049
6 months+0.21%€1,002
Year to date+14.55%€1,146
1 year+21.60%€1,216
3 years+46.92%€1,469
5 years+83.00%€1,830
10 years+214.41%€3,144

From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment

The chart in detail

Fagron: technical analysis

Fagron shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 41.2% below its all-time closing high (€41.48, August 5, 2014).

Trend
No clear trend
RSI (14 sessions)
62
Between 30 and 70
vs 200-session average
+5.66%

Support and resistance

Price areas where Fagron has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance€25.05+2.66%2 touches, last on June 10, 2026
  2. Resistance€24.80+1.64%3 touches, last on November 10, 2026
  3. Last price€24.40
  4. Support€23.98−1.71%3 touches, last on July 30, 2026
  5. Support€23.60−3.28%4 touches, last on September 28, 2026
  6. Support€23.30−4.51%3 touches, last on November 2, 2026

Volatility and risk

Volatility (60 sessions, annualised)
23.5%
Largest fall in the last year
−16.83%

Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Fagron: seasonality

Average monthly price change over 19 years

+2.6%Jan+3.9%Feb+2.5%Mar+6.3%Apr+2.5%May−2.7%Jun−0.1%Jul−0.6%Aug−0.7%Sep−0.5%Oct−3.5%Nov+1.9%Dec

Over the last 19 years, the strongest month for Fagron has been April: +6.27% on average, positive in 16 years out of 19. The weakest has been November: −3.52% on average, positive in 8 years out of 19.

Show chart data
MonthAverageMedianPositive years
January+2.58%+2.26%12 of 19
February+3.89%+2.39%12 of 19
March+2.47%+2.41%11 of 19
April+6.27%+7.18%16 of 19
May+2.48%+0.42%10 of 19
June−2.69%−3.19%8 of 19
July−0.07%−2.97%7 of 19
August−0.62%+1.37%13 of 19
September−0.74%−2.07%6 of 19
October−0.55%+0.21%11 of 19
November−3.52%−0.63%8 of 19
December+1.94%+3.96%12 of 19

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Fagron and its competitors

Pharmacies and hospitals know Fagron NV through brands such as DiluCap excipients, DiluTab, Pigmerise, Nourisil MD and SyrSpend SF, along with the Neogen and TrichoConcept hair care lines. The company, formerly known as Arseus NV until it changed its name in January 2015, provides personalized pharmaceutical care to hospitals, pharmacies, clinics and patients in markets worldwide. Its activity is organized in three segments: Essentials, Brands and Compounding Services. It also trains prescribers, hospitals and pharmacists through the Fagron Academy.

Headquarters
Nazareth, Belgium
Employees
4,880
Founded
1990
Chief executive
Rafael Padilla
Fagron and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
FagronFAGR$1.9B14.3%18.8+0.21%
Faes FarmaFAE$1.73B13.0%18.7+9.03%
AlmirallALM$2.53B9.6%32.1−7.24%
Siegfried HoldingSFZN$3.53B16.7%17.3−14.20%
Laboratorios Farmaceuticos RoviROVI$3.93B20.2%17.4+16.20%
PharmaNutraPHN$875.44M21.7%35.0−3.45%

Same industry or related industries, similar size. Compare Fagron with its competitors · Full profile